Status:
AVAILABLE
Treatment of Dravet Syndrome With Fenfluramine (Expanded Access Protocol)
Lead Sponsor:
University of California, Los Angeles
Conditions:
Dravet Syndrome
Eligibility:
All Genders
2+ years
Brief Summary
The purpose of this research study is to (1) provide access to fenfluramine for patients with intractable epilepsy associated with Dravet syndrome, and (2) evaluate the safety of fenfluramine.
Detailed Description
The purpose of this research study is to (1) provide access to fenfluramine for patients with intractable epilepsy associated with Dravet syndrome, and (2) evaluate the safety of fenfluramine.
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Genetic diagnosis of Dravet syndrome with intractable seizures despite failing all available medications for seizures.
Exclusion
Key Trial Info
Start Date :
Trial Type :
EXPANDED_ACCESS
End Date :
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT04437004
Last Update
June 18 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of California, Los Angeles
Los Angeles, California, United States, 90095-1752